Be Clinical, a skincare brand, has raised Rs 6 crore in a seed fundraising round headed by V3 Ventures. Titan Capital, which was founded by Kunal Bahl and Rohit Bansal, has joined the round and boosted its support for the brand.

Key Highlights

• Be Clinical raised ₹6 crore in seed funding led by V3 Ventures with Titan Capital participation.
• Proceeds will support R&D, clinical testing, manufacturing expansion, and development of targeted anti-ageing skincare solutions.

The Mumbai-based company had previously raised Rs 2 crore in the same funding round, which was headed by Titan Capital and included Aditya Agarwal, the founder of P-TAL.

According to a news statement from Be Clinical, the funds will be utilized for research and development to improve internal formulation skills, carry out clinical testing, and provide focused remedies for ageing issues affecting the face, body, and scalp.

Be Clinical, an evidence-based skincare brand created especially for Indian skin and conditions, was introduced in May of last year by Hemangi Dhir. It offers clinically proven remedies for aging skin. The company tackles aging issues with a strong emphasis on transparency, education, and quantifiable outcomes, supported by internal research and dermatologically active substances.

Be Clinical seeks to fill a vacuum in the Indian skincare market, such as the absence of transparent, clinically proven, and science-led products made especially for Indian skin and environmental circumstances. According to the company, it sets itself apart with in-vivo tested, scientifically validated formulations that are backed by responsible formulation, end-to-end in-house research, and production.

Also Read: EV Charging Startup RoadGrid Bags Rs 12 Cr in Pre-Series A Funding

Be Clinical asserts that since its founding, it has served over 25,000 clients and shown strong early momentum in a brief amount of time, demonstrating quick adoption and growing consumer trust in its professionally based, India-specific skincare products.

In order to increase production capacity, consistency, and quality control, the company intends to add cutting-edge machinery to its manufacturing facilities. In order to maintain ingredient performance and uphold the brand's clinical-grade status, the company hopes to improve packaging with premium, protective, and functional formats.